Genetic Signatures (GSS) H2 2024 earnings summary

Executive summary

• Revenue declined 42% year-over-year to $9.8 million, mainly due to the temporary withdrawal of the EasyScreen Respiratory Pathogen Detection Kit in Australia during peak flu season, impacting sales significantly.

• Net loss increased 27% year-over-year to $17.9 million, reflecting lower sales and reduced gross margins.

• Achieved a major milestone with US FDA 510(k) clearance for the EasyScreen Gastrointestinal Parasite Detection Kit, opening the US market for commercialisation.

• Two capital raises in FY2024 provided $35 million, strengthening the balance sheet and supporting future growth initiatives.

• Leadership transition: Dr. John Melki stepped down as CEO, with Neil Gunn as Interim CEO and Allison Rossiter appointed to commence as CEO in September 2024.

Financial highlights

• Revenue from ordinary activities: $9.8 million, down 42% year-over-year.

• Net loss after tax: $17.9 million, up 27% year-over-year.

• Gross margin on materials: 53%, down from 60% in the prior year due to lower production volumes and increased inventory obsolescence.

• Cash on hand at year-end: $36.3 million; company remains debt free.

• Net operating cash outflow: $10.1 million, with $10.6 million in customer receipts and $6.9 million in R&D tax incentives received.

Outlook and guidance

• Focus on commercialising the EasyScreen Gastrointestinal Parasite Detection Kit in the US, with expectations for solid revenue growth in FY2025 and beyond.

• Plans to resume paused R&D and instrument development activities as cash flows improve.

• Expansion of the European customer base and continued investment in new product development.